The evolution of patient management in infectious and autoimmune diseases in the post-COVID-19
DOI:
https://doi.org/10.52692/1857-0011.2025.3-83.39Keywords:
autoimmune diseases, infectious diseases, telemedicine, digital biomarkers, vaccination, multiple sclerosisAbstract
Aim: To examine the changes implemented and emerging trends in managing patients with autoimmune and infectious
neurologic pathology in the postCOVID-19 period, with focus on clinical and epidemiological experience.
Materials and Methods: A systematic literature review was carried out following PRISMA criteria, using Google Scholar and PubMed databases. Keywords included: „neuromuscular diseases”, „infectious disease”, „multiple sclerosis”,
„autoimmune diseases”, „telemedicine”, „post-Covid-19 era”. Articles published between 2023–2025 were considered; 369 articles were initially identified, of which 24 were included after screening titles and abstracts.
Results: Telemedicine and telerehabilitation have become important complementary tools for patients with multiple sclerosis and other autoimmune diseases, although limitations remain in terms of access and technological literacy. The use of digital devices and digital biomarkers for monitoring is increasing, but further validation is needed. In infectious pathology, after easing restrictions there is a notable rise in the incidence of bacterial and viral meningitis, partly due to decreased vaccination coverage. For autoimmune disease patients, challenges include adapting immunosuppressive or biologic therapies after SARS-CoV-2 infection, and ensuring multidisciplinary care.
Conclusions: Management of autoimmune and infectious pathologies in the post-COVID-19 era requires more flexible and personalized care models, strengthening digital infrastructure, epidemiological surveillance and vaccination programs, as well as integrating digital biomarkers and multidisciplinary teams for optimal patient outcomes.
References
Bloem, B. R., Dorsey, E. R. & Okun, M. S. The Coronavirus Disease 2019 Crisis as Catalyst for Telemedicine for Chronic Neurological Disorders. JAMA Neurol 77, 927–928 (2020).
Prosperini, L. et al. COVID-19 and multiple sclerosis: challenges and lessons for patient care. The Lancet Regional Health - Europe 44, (2024).
Sumner, L. et al. Use of Telemedicine Among People with Multiple Sclerosis Before and During the COVID-19 Pandemic. Telemed J E Health 29, 1152–1163 (2023).
Krett, J. D., Salter, A. & Newsome, S. D. Era of COVID-19 in Multiple Sclerosis Care. Neurol Clin 42, 319–340 (2024).
Landi, D. et al. Patient’s point of view on the use of telemedicine in multiple sclerosis: a web-based survey. Neurol Sci 43, 1197–1205 (2022).
Truijen, S. et al. Effect of home-based virtual reality training and telerehabilitation on balance in individuals with Parkinson disease, multiple sclerosis, and stroke: a systematic review and meta-analysis. Neurol Sci 43, 2995– 3006 (2022).
Seron, P. et al. Effectiveness of Telerehabilitation in Physical Therapy: A Rapid Overview. Phys Ther 101, (2021).
Channa, A., Popescu, N., Skibinska, J. & Burget,
R. The Rise of Wearable Devices during the COVID-19 Pandemic: A Systematic Review. Sensors (Basel) 21, (2021).
Sparaco, M., Lavorgna, L., Conforti, R., Tedeschi, G. & Bonavita, S. The Role of Wearable Devices in Multiple Sclerosis. Mult Scler Int 2018, 1–7 (2018).
Salaorni, F., Bonardi, G., Schena, F., Tinazzi, M. & Gandolfi, M. Wearable devices for gait and posture monitoring via telemedicine in people with movement disorders and multiple sclerosis: a systematic review. Expert Rev Med Devices 21, 121–140 (2024).
Vacchi, L., Zirone, E., Strina, V., Cavaletti, G. & Ferrarese, C. Mobile Applications to Support Multiple Sclerosis Communities: The Post-COVID-19 Scenario. Telemed J E Health 30, e1615–e1628 (2024).
Bertran Recasens, B. & Rubio, M. A. Neuromuscular Diseases Care in the Era of COVID-19. Front Neurol 11, (2020).
Zubair, A. S., Zubair, A. S. & Desai, K. Chronic Inflammatory Demyelinating Polyradiculoneuropathy During the COVID-19 Pandemic: Telemedicine Limitations and Strategies for Improvement. Cureus 13, (2021).
Lee, H. et al. Anti-N-methyl-D-aspartate receptor encephalitis after coronavirus disease 2019: A case report and literature review. Medicine 101, E30464 (2022).
Sanchez, C. V., Theel, E., Binnicker, M., Toledano,
M. & McKeon, A. Autoimmune encephalitis after SARS- CoV-2 infection. Neurology 97, E2262–E2268 (2021).
Dahshan, A. & Abdellatef, A. A. Autoimmune encephalitis as a complication of COVID-19 infection: a case report. Egypt J Intern Med 34, (2022).
Que, X. et al. The characteristic change of autoimmune encephalitis after the COVID-19 epidemic in Guangxi, China. Sci Rep 15, (2025).
Michael, B. D. et al. Para-infectious brain injury in COVID-19 persists at follow-up despite attenuated cytokine and autoantibody responses. Nat Commun 14, (2023).
Wood, G. K. et al. Posthospitalization COVID-19 cognitive deficits at 1 year are global and associated with
elevated brain injury markers and gray matter volume reduction. Nat Med 31, 245–257 (2025).
Taquet, M. et al. Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1 284 437 patients. Lancet Psychiatry 9, 815–827 (2022).
Farias, L. A. B. G. et al. Alterations and Dynamics of Major Meningitis Etiological Agents During and Post- COVID-19 Pandemic: A Systematic Review. Trop Med Infect Dis 10, (2025).
Lee, P. I., Hsueh, P. R., Chuang, J. H. & Liu, M.
T. Changing epidemic patterns of infectious diseases during and after COVID-19 pandemic in Taiwan. Journal of Microbiology, Immunology and Infection 57, 685–690 (2024).
Bloom, D. E. et al. Meningococcal Disease in the Post-COVID-19 Era: A Time to Prepare Infect Dis Ther 12, 2649–2663 (2023)..
Džupová, O., Bartoš, H., Sýkorová, B. & Beneš, J. Changing trends in Streptococcus pyogenes bacteraemia in adults in the post-COVID era. BMC Infect Dis 25, (2025).
Downloads
Published
License
Copyright (c) 2026 Bulletin of the Academy of Sciences of Moldova. Medical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
